Lorlatinib (lorlatinib)

Lorlatinib is approved for: Metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test (single FDA indication covering first-line and previously treated patients). It is a lorlatinib (Third-generation ALK/ROS1 tyrosine kinase inhibitor), originally marketed as Lorbrena (US, Canada, Japan); Lorviqua (EU) by Pfizer Inc..

Lorlatinib is a small molecule (oral tablet), but it is NOT a generic in any regulated sense: no FDA- or EMA-approved generic or abridged version of lorlatinib exists, and the originator product Lorbrena/Lorviqua remains patent-protected and is the only approved source in the US, EU and most markets. Because there is no approved generic, no bioequivalence data exist for any copy. Standard small-molecule rules would apply to any future generic: a bioequivalence study showing AUC and Cmax confidence intervals within 80-125% of the reference product. Head-to-head efficacy trials and immunogenicity (anti-drug antibody) testing are irrelevant for a small-molecule drug of this type, in contrast to biosimilars. Non-originator lorlatinib products marketed in Bangladesh and Laos have not been assessed against FDA/EMA standards in this research and their regulatory status is not verifiable from the sources cited. Manufacturers supplying lorlatinib generic versions include Beacon Pharmaceuticals PLC, Drug International Ltd., Everest Pharmaceuticals Ltd., Lucius Pharmaceuticals, Pfizer Ltd.. Brands registered in Bangladesh include Loranix, Lorbrexen.

Standard dosing for lorlatinib: 100 mg taken orally once daily, with or without food, at the same time each day, until disease progression or unacceptable toxicity. Swallow tablets whole; do not chew, crush or split. If a dose is missed, take it unless the next dose is due within 4 hours; do not double-dose. Dose adjustments: Dose reduction levels: first reduction 75 mg once daily, second reduction 50 mg once daily; permanently discontinue if 50 mg once daily is not tolerated. Severe hepatic impairment (Child-Pugh C): 50 mg once daily. Creatinine clearance 15 to <30 mL/min: 75 mg once daily. Strong CYP3A inhibitors: avoid; if unavoidable reduce starting dose to 75 mg once daily (or 50 mg if already reduced), and avoid fluconazole similarly. Strong CYP3A inducers: contraindicated (risk of serious hepatotoxicity). Moderate CYP3A inducers: avoid, or if unavoidable increase lorlatinib to 125 mg once daily. No adjustment needed for mild hepatic impairment or mild/moderate renal impairment.

Lorlatinib blocks the abnormal ALK protein that drives ALK-positive lung cancer cells to grow and divide. It was engineered to cross into the brain and to keep working against tumours that have become resistant to earlier ALK drugs such as crizotinib, alectinib and ceritinib. Technically: Lorlatinib (PF-06463922) is an oral, reversible, ATP-competitive macrocyclic inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and ROS1. It binds the ATP-binding pocket of the kinase domain, inhibiting ALK autophosphorylation and downstream PI3K/AKT/mTOR and RAS/RAF/MEK/ERK signalling that drives proliferation and survival. It has in vitro activity against multiple mutant forms of ALK, including the G1202R and I1171T solvent-front/resistance mutations emerging on earlier-generation ALK inhibitors, and is also active in vitro against TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2 and ACK. Its macrocyclic structure and low efflux liability give excellent CNS penetration, with intracranial activity demonstrated in mice implanted intracranially with EML4-ALK-driven tumour cells.

The most frequently reported side effects of lorlatinib are edema (swelling), peripheral neuropathy, cognitive effects (memory, attention, speech), weight gain, fatigue, dyspnea, arthralgia. Serious but less common reactions include atrioventricular block / pr-interval prolongation. Routine monitoring: Serum cholesterol and triglycerides before starting and periodically during treatment (hyperlipidemia is near-universal and may require statins); Blood pressure every 2 to 4 weeks (Grade 3-4 hypertension occurs and needs control or drug hold); ECG / heart rate for AV block and PR-interval prolongation. Report any new or worsening symptom to your treating physician — most adverse effects are managed by dose reduction rather than stopping treatment.

Lorlatinib (Third-generation ALK/ROS1 tyrosine kinase inhibitor (oral small-molecule kinase inhibitor; ALK inhibitor), originally Lorbrena (US, Canada, Japan); Lorviqua (EU) by Pfizer Inc.) Lorlatinib blocks the abnormal ALK protein that drives ALK-positive lung cancer cells to grow and divide. It was engineered to cross into the brain and to keep working against tumours that have become resistant to earlier ALK drugs such as crizotinib, alectinib and ceritinib. 100 mg taken orally once daily, with or without food, at the same time each day, until disease progression or unacceptable toxicity. Swallow tablets whole; do not chew, crush or split. If a dose is missed, take it unless the next dose is due within 4 hours; do not double-dose.

Lorlatinib (Third-generation ALK/ROS1 tyrosine kinase inhibitor (oral small-molecule kinase inhibitor; ALK inhibitor), originally Lorbrena (US, Canada, Japan); Lorviqua (EU) by Pfizer Inc.) Lorlatinib blocks the abnormal ALK protein that drives ALK-positive lung cancer cells to grow and divide. It was engineered to cross into the brain and to keep working against tumours that have become resistant to earlier ALK drugs such as crizotinib, alectinib and ceritinib. 100 mg taken orally once daily, with or without food, at the same time each day, until disease progression or unacceptable toxicity. Swallow tablets whole; do not chew, crush or split. If a dose is missed, take it unless the next dose is due within 4 hours; do not double-dose.

Lorlatinib is a small molecule (oral tablet), but it is NOT a generic in any regulated sense: no FDA- or EMA-approved generic or abridged version of lorlatinib exists, and the originator product Lorbrena/Lorviqua remains patent-protected and is the only approved source in the US, EU and most markets. Because there is no approved generic, no bioequivalence data exist for any copy. Standard small-molecule rules would apply to any future generic: a bioequivalence study showing AUC and Cmax confidence intervals within 80-125% of the reference product. Head-to-head efficacy trials and immunogenicity (anti-drug antibody) testing are irrelevant for a small-molecule drug of this type, in contrast to biosimilars. Non-originator lorlatinib products marketed in Bangladesh and Laos have not been assessed against FDA/EMA standards in this research and their regulatory status is not verifiable from the sources cited. Manufacturers supplying lorlatinib generic versions include Beacon Pharmaceuticals PLC, Drug International Ltd., Everest Pharmaceuticals Ltd., Lucius Pharmaceuticals, Pfizer Ltd.. Brands registered in Bangladesh include Loranix, Lorbrexen.

Bangladesh benchmark: 2 manufacturers sell generic lorlatinib 100 mg; unit prices range from BDT 1,660 (US$13.51) to BDT 1,660 (US$13.51), i.e. about US$405.31–US$405.31 per 30 units. Cheapest listed brand: Loranix (Beacon Pharmaceuticals PLC) at BDT 1,660 per unit. Prices move with pack size, pharmacy and the exchange rate — confirm current stock and price with a licensed importer before ordering.

Dose reduction levels: first reduction 75 mg once daily, second reduction 50 mg once daily; permanently discontinue if 50 mg once daily is not tolerated. Severe hepatic impairment (Child-Pugh C): 50 mg once daily. Creatinine clearance 15 to <30 mL/min: 75 mg once daily. Strong CYP3A inhibitors: avoid; if unavoidable reduce starting dose to 75 mg once daily (or 50 mg if already reduced), and avoid fluconazole similarly. Strong CYP3A inducers: contraindicated (risk of serious hepatotoxicity). Moderate CYP3A inducers: avoid, or if unavoidable increase lorlatinib to 125 mg once daily. No adjustment needed for mild hepatic impairment or mild/moderate renal impairment. Drug interactions matter most with strong CYP3A4 inducers/inhibitors and with other medicines that prolong the QT interval or suppress the immune system. Always show your full medication list to the prescribing physician.